- Report
- May 2024
- 183 Pages
From €4662EUR$4,900USD£3,992GBP
- Report
- January 2019
- 89 Pages
Global
From €4710EUR$4,950USD£4,033GBP
- Report
- July 2021
- 115 Pages
Global
From €4519EUR$4,750USD£3,870GBP
- Report
- April 2019
- 188 Pages
Europe
From €1998EUR$2,100USD£1,711GBP
€2854EUR$3,000USD£2,444GBP
- Report
- May 2024
- 200 Pages
From €3949EUR$4,150USD£3,381GBP
- Report
- December 2022
- 95 Pages
North America
From €1427EUR$1,500USD£1,222GBP
- Report
- May 2022
- 200 Pages
Global
From €3425EUR$3,600USD£2,933GBP
- Report
- May 2022
- 78 Pages
Asia Pacific
From €1427EUR$1,500USD£1,222GBP
- Report
- June 2021
- 130 Pages
Global
€3990EUR$4,492USD£3,536GBP
- Report
- August 2018
- 88 Pages
Global
From €4519EUR$4,750USD£3,870GBP
- Report
- November 2021
- 1165 Pages
Global
From €5709EUR$6,000USD£4,888GBP
- Report
- July 2023
- 140 Pages
Global
From €5708EUR$5,999USD£4,887GBP
- Book
- October 2020
- 288 Pages
- Book
- June 2022
North America
- Book
- June 2020
North America
Circulating Tumor DNA (ctDNA) is a type of genetic material found in the bloodstream of cancer patients. It is a valuable tool for cancer diagnosis, prognosis, and treatment. ctDNA can be used to detect the presence of cancer, identify the type of cancer, and monitor the progression of the disease. It can also be used to detect mutations in cancer cells, which can help guide treatment decisions.
ctDNA is a rapidly growing field in genomics, with many companies developing technologies to detect and analyze ctDNA. These companies are developing technologies such as next-generation sequencing, digital PCR, and microfluidics to detect and analyze ctDNA. Companies are also developing technologies to detect and analyze ctDNA in real-time, allowing for more accurate and timely diagnosis and treatment.
Some companies in the ctDNA market include Illumina, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, and Guardant Health. Show Less Read more
